Savara Inc. (SVRA)
NASDAQ: SVRA · Real-Time Price · USD
2.955
+0.255 (9.44%)
Aug 14, 2025, 12:04 PM - Market open
Savara Employees
Savara had 59 employees as of December 31, 2024. The number of employees increased by 22 or 59.46% compared to the previous year.
Employees
59
Change (1Y)
22
Growth (1Y)
59.46%
Revenue / Employee
n/a
Profits / Employee
-$1,870,034
Market Cap
622.59M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 59 | 22 | 59.46% |
Dec 31, 2023 | 37 | 9 | 32.14% |
Dec 31, 2022 | 28 | 6 | 27.27% |
Dec 31, 2021 | 22 | -5 | -18.52% |
Dec 31, 2020 | 27 | -13 | -32.50% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
SVRA News
- 1 day ago - Savara Reports Second Quarter 2025 Financial Results and Provides a Business Update - Business Wire
- 26 days ago - Savara Announces New Employment Inducement Grant - Business Wire
- 2 months ago - Savara Inc. Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation - Accesswire
- 2 months ago - Why Is Rare Lung Disease-Focused Savara Stock Trading Lower On Tuesday? - Benzinga
- 2 months ago - BREAKING: Savara Shares Down Over 30%; Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses - GlobeNewsWire
- 2 months ago - Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP) - Business Wire
- 3 months ago - Savara Announces Participation in Jefferies Global Healthcare Conference - Business Wire
- 3 months ago - Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic Society Conference (ATS) 2025 - Business Wire